Initiate Phase 2 clinical trial for A-005 in multiple sclerosis
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 6 Feb 2025
- Due
- 31 Dec 2025
- Checked
- 13 Sep 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“initiation of its Phase 2 clinical trial in MS in the second half of 2025”
What we found
Evidence strength B What the grades mean
Alumis (post-merger with ACELYRIN) repeatedly delayed the A-005 Phase 2 MS trial start, first to H1 2026, then left the timing undetermined as of March 2026.
-
B Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Reaffirms A-005 Phase 2 initiation anticipated H1 2026, not yet started
-
D Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Original commitment: Phase 2 MS trial expected to start 2H 2025
-
D Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update Timeline pushed back: A-005 Phase 2 now anticipated H1 2026
-
D Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements As of March 2026, no firm start date; timing update promised for Q2 2026
Checked 13 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second checkThe evidence document could not be read for a second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Acelyrin, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-C962918-000357 · Corrections policy